Non-dilutive funding for biotech startups: the complete landscape (CPRIT, NIH/SBIR, NCI programs, in-kind support)

Non-dilutive funding for a biotech startup comes from four main sources: federal SBIR and STTR grants led by NIH, institute-specific mechanisms such as NCI's late-stage awards, state programs such as CPRIT in Texas, and in-kind development support from NIH centers and disease foundations. Each pays for work without taking equity, but each carries its own timeline, matching requirement, data-rights terms, and reporting burden.

What counts as non-dilutive funding, and what does it really cost?

Non-dilutive funding is capital that does not take ownership in the company. Grants, government contracts, in-kind services, and revenue-sharing awards all qualify. Over my career I have secured more than $25M in competitive non-dilutive funding and in-kind support across CPRIT, NCI, and NIH/SBIR programs. Non-dilutive does not mean free. The real costs are time, control, and compliance.

How do NIH SBIR and STTR awards work in 2026?

SBIR and STTR are statutory set-asides. Federal agencies with large extramural research budgets must direct 3.2% of that budget to SBIR and 0.45% to STTR, and NIH alone commits more than $1.4 billion per year to these programs [1]. Phase I supports feasibility work and Phase II supports full development, as grants or contracts, never equity [1].

NIH's standard caps are $323,090 for a Phase I project of six months to two years and $2,153,927 for a Phase II project of one to three years [1]. HHS holds SBA approval to exceed those caps for listed topics, and NCI's approved list includes therapeutics such as small molecules, biologics, and cell and gene therapies [2].

Eligibility rules shape who leads. For SBIR, the principal investigator must have primary employment with the small business, meaning more than half of their time [3]. STTR allows the investigator to be employed by the partnering research institution, but the small business must perform at least 40% of the work and the institution at least 30% [3].

Timing is slower than most founders expect. NIH's small business due dates are September 5, January 5, and April 5. For the September cycle, scientific review runs October to November, council meets in January, and the earliest start is April [4]. Seven months is the best case.

Authorization risk is not hypothetical. The programs' legislative authority expired on October 1, 2025, and NIH expired all open SBIR and STTR funding opportunities and paused noncompeting continuation awards [5]. Reauthorization was signed on April 13, 2026, extending the programs through September 30, 2031 [6]. I now advise clients to hold reserves that cover a lapse of at least two quarters.

What does NCI add beyond a standard SBIR award?

NCI's mechanisms reach further into development than most institutes. The Phase IIB Strategic Breakthrough Award funds late-stage clinical development of therapeutics and devices for pediatric and rare cancers, with up to $15 million over a four-year project period [7]. Applicants must have received a qualifying Phase II award and must secure third-party funding equal to 100% of the NIH request [7].

The outcome data justify the effort. The National Academies' 2022 assessment linked NIH SBIR and STTR awardees to at least 99 drugs, 34 PMA devices, and 2,475 510(k) clearances since the programs began [8]. Less than 4 percent of NIH's extramural research budget flows through these programs, so competition is intense [8].

How do CPRIT product development awards differ from federal grants?

CPRIT, the Cancer Prevention and Research Institute of Texas, funds companies rather than investigators. Its Product Development Research program has roughly $70 million per fiscal year available, supports three-year projects, and caps only the Seed Company Award, at $3 million per project [9]. Therapeutics applicants may request any amount appropriate to the work [9].

Two obligations distinguish CPRIT from NIH. Companies receiving $20 million or less must spend at least $1 of their own funds for every $2 of CPRIT funds, at the same time, with no credit for in-kind or prior spending; above $20 million cumulative the match becomes dollar for dollar [10]. The company must also meet Texas location criteria within one year of first disbursement [10].

CPRIT also takes a share of revenue. For therapeutic programs the state receives 3%, 4%, or 5% of revenue, stepping with cumulative sales, until it has been paid four times the grant amount, and payments begin only after product sales exceed $5 million [11]. A continuing 0.5% royalty applies after that cap is reached, and no pre-revenue milestones are shared [11].

On the rare pediatric leukemia biologic I led, a CPRIT product development award and a later supplemental award funded IND-enabling work at a scale NIH mechanisms could not have covered. The matching obligation forced disciplined private fundraising in parallel from the start.

Which in-kind and foundation programs are worth pursuing?

In-kind programs provide work rather than cash. NCI's Experimental Therapeutics program, NExT, supports selected projects through NCI contracts covering discovery, IND-enabling GMP and GLP work, and early trials; it awards no grants and currently runs application cycles ad hoc [12]. NCATS TRND similarly provides expertise and resources to move rare disease therapeutics through preclinical testing toward an IND [13].

The tradeoff with in-kind support is control. Government contractors run the studies on their schedule, and new intellectual property may be shared. On programs I have led, in-kind work paid for studies we could not otherwise fund, and it was the slowest line on the schedule.

Disease foundations and patient organizations are a growing fourth source. A 2026 guide in Nature Reviews Drug Discovery describes nonprofit models that fund and steward drug development where conventional commercial systems fall short [14]. These awards are often smaller than federal grants, but they bring disease expertise, patient access, and advocacy that money cannot buy.

How do the programs compare, and in what order should a founder pursue them?

Data rights are the string founders most often overlook. Under the SBA policy directive, SBIR and STTR data carry a uniform 20-year protection period that begins on the award date, during which the government may use the data but may not disclose it [15]. It is strong but finite; reconcile it with your patent strategy early.

My sequencing advice is simple. Use SBIR Phase I or a foundation award to generate the data that makes a Phase II or CPRIT application credible. Pursue CPRIT once you can meet the match and the Texas commitment. Treat NCI's late-stage awards and in-kind programs as accelerators that require private capital or patience. None of them replace investors.

This article is part of the Life Sciences Consulting practice at Hamilton Atlas Group — see the full capability list there.

References

1. National Institutes of Health SEED. Understanding SBIR and STTR. NIH, 2026.
2. U.S. Department of Health and Human Services. Approved SBIR/STTR Topics for Awards over Statutory Budget Limitations. NIH SEED, 2024.
3. National Institutes of Health. 18.5 Small Business Innovation Research and Small Business Technology Transfer Programs. NIH Grants Policy Statement, 2025.
4. National Institutes of Health. Standard Due Dates. NIH Grants & Funding, 2026.
5. National Institutes of Health. NOT-OD-26-006: Notice of Early Expiration of NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Notices of Funding Opportunity and Guidance for Existing Recipients. NIH, 2025.
6. National Institutes of Health. It's Official: NIH's Small Business Program Is Back. NIH Extramural Nexus, 2026.
7. National Cancer Institute. Phase IIB Strategic Breakthrough Award. NCI SBIR Development Center, 2026.
8. National Academies of Sciences, Engineering, and Medicine. Assessment of the SBIR and STTR Programs at the National Institutes of Health. The National Academies Press, 2022.
9. Cancer Prevention and Research Institute of Texas. Product Development Research. CPRIT, 2026.
10. Cancer Prevention and Research Institute of Texas. RFA C-26.1-TTC: Texas Therapeutics Company Awards for Product Development Research. CPRIT, 2025.
11. Cancer Prevention and Research Institute of Texas. Revenue Sharing. CPRIT, 2026.
12. National Cancer Institute. NCI Experimental Therapeutics Program (NExT). NCI Division of Cancer Treatment and Diagnosis, 2026.
13. National Center for Advancing Translational Sciences. Therapeutics for Rare and Neglected Diseases (TRND). NIH NCATS, 2026.
14. Reichel M, Nasto B, Coch C, Steiner M, Murauer EM, Trübel H. A guide to effective drug development through nonprofit models. Nature Reviews Drug Discovery. 2026.
15. U.S. Small Business Administration. What are SBIR data rights and why are they important? SBIR.gov, 2026.